Medical Research Finder

Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

© 2026 meRfi®

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

AuthorsReferences (Sources)

meRfi® AI Chat

Biomarker & Immune checkpoint inhibitors (ICIs)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

Register for a free trial

Navigation

Contents

Cancer immunotherapy with checkpoint blockade is now a standard treatment for many cancers, but predictive biomarkers are still needed. Emerging evidence suggests the host microbiome may predict immunotherapy response, though the ideal microbiome is not yet defined.
Malczewski et al. 2020

see also:
Akkermansia muciniphila & Anti-PD-1 antibodies / PD-1 inhibitors
Cancer Immunotherapy / Immuno-Oncology & Gut microbiota
Circulating tumor DNA (ctDNA) & Immune checkpoint inhibitors (ICIs)
[Gut microbiota & Immune Checkpoint Inhibitors (ICIs)](brain://EYkPfvAgvE…

References (Sources)

Association of peripheral blood absolute lymphocyte count (ALC) and clinical activity in patients (pts) with advanced melanoma treated with ipilimumab
Berman et al. 2009 J Clin Oncol 27:15s (suppl. abstract 3020)
Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer.
Derosa et al. 2022 Nat. Med. 28: 315-324
Microbiome-derived metabolome as a potential predictor of response to cancer immunotherapy
Malczewski et al. 2020
Predictive biomarkers for checkpoint inhibitor-based immunotherapy
Gibney et al. 2016 Lancet Oncol. 17(12): e542-e551
Review
Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival.
Ku et al. 2010 Cancer 116: 1767–75
Too much water drowned the miller: Akkermansia determines immunotherapy responses
Li & McAllister 2022 Cell Rep Med 3(5): 100642
Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence
Klempner et al. 2020
Review

AI Chat

7/1/2026

Chat with our artificial intelligence: